Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.64 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.51 |
| ▸ | ACLY | P53396 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345607 | 0.85 | CYP19A1 (0.74) | CYP19A1CYP11B1CYP11B2SLC2A1NR4A2 | |
| SCHEMBL10168717 | 0.85 | MKNK1 (0.70) | KDRMKNK1MKNK2ALDH1A1MAPT | |
| SCHEMBL10028698 | 0.81 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP11B2SLC2A1NR4A2 | |
| SCHEMBL14212113 | 0.80 | CYP19A1 (0.51) | CYP19A1CYP11B1CYP11B2SLC2A1KDR | |
| SCHEMBL13912438 | 0.79 | SCN9A (0.49) | ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL14626526 | 0.79 | CYP11B2 (0.58) | CYP19A1CYP11B1CYP11B2KDRMKNK1 | |
| SCHEMBL13044192 | 0.79 | CYP11B1 (0.64) | CYP19A1CYP11B1CYP11B2SLC2A1NR4A2 | |
| SCHEMBL3511516 | 0.79 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP11B2SLC2A1NR4A2 | |
| SCHEMBL4509922 | 0.78 | CYP11B2 (1.00) | CYP19A1CYP11B1CYP11B2SLC2A1NR4A2 | |
| SCHEMBL13188366 | 0.78 | CYP11B1 (0.67) | CYP19A1CYP11B1CYP11B2SLC2A1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534680-B1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACO INVESTMENTS INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7501446-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20070149549-A1 | 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2007-06-28 | — | — | US | disclosed |
| US-7166619-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY , INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149549-A1 | 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors | FNTA, PTAR1, ZMPSTE24 | CYP19A1 3617/4885CYP11B1 963/4885CYP11B2 1033/4885 |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | RCE1, GGPS1, FNTA | CYP19A1 3347/4885CYP11B1 225/4885CYP11B2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.